FY2025 Earnings Forecast for Biogen Issued By William Blair

Key Points

• William Blair raised their FY2025 earnings per share (EPS) forecast for Biogen to $15.89, up from a prior estimate of $15.76, while maintaining an "Outperform" rating on the stock.
• Biogen reported a quarterly EPS of $5.47, surpassing analyst expectations of $3.93, and saw a 7.3% year-over-year revenue increase to $2.65 billion.
• The company has set FY 2025 EPS guidance between $15.50 and $16.00, while the stock had a recent market cap of $21.49 billion.

Biogen Inc. (NASDAQ:BIIB - Free Report) - William Blair boosted their FY2025 earnings per share (EPS) estimates for Biogen in a research note issued on Friday, October 10th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of $15.89 per share for the year, up from their prior estimate of $15.76. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's FY2026 earnings at $15.07 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, topping analysts' consensus estimates of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same period in the previous year, the company posted $5.28 earnings per share. The business's revenue for the quarter was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

BIIB has been the subject of a number of other reports. HC Wainwright upped their price target on Biogen from $187.00 to $194.00 and gave the company a "buy" rating in a report on Friday, August 1st. Royal Bank Of Canada decreased their price target on Biogen from $219.00 to $217.00 and set an "outperform" rating for the company in a report on Wednesday, October 8th. Needham & Company LLC restated a "hold" rating on shares of Biogen in a research report on Wednesday, September 24th. Truist Financial initiated coverage on shares of Biogen in a research report on Monday, July 21st. They set a "hold" rating and a $142.00 target price on the stock. Finally, Wall Street Zen raised Biogen from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 28th. Eleven analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biogen presently has a consensus rating of "Hold" and an average target price of $180.15.

Biogen Stock Performance

Shares of BIIB stock opened at $146.57 on Monday. The firm has a fifty day moving average price of $140.21 and a 200 day moving average price of $131.09. The company has a market cap of $21.49 billion, a P/E ratio of 14.01, a PEG ratio of 1.16 and a beta of 0.13. Biogen has a 12 month low of $110.04 and a 12 month high of $194.13. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 517 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider owned 5,772 shares of the company's stock, valued at $770,850.60. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Biogen

Large investors have recently modified their holdings of the company. Opal Wealth Advisors LLC purchased a new position in Biogen in the first quarter valued at about $26,000. Greykasell Wealth Strategies Inc. bought a new stake in Biogen during the first quarter valued at $27,000. Vision Financial Markets LLC bought a new stake in shares of Biogen during the 1st quarter valued at about $27,000. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen during the second quarter valued at approximately $25,000. Finally, Zions Bancorporation National Association UT bought a new position in Biogen during the 1st quarter worth $29,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.